Topiramate - Safety and tolerability

被引:51
作者
Jones, MW [1 ]
机构
[1] Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
10.1017/S0317167100034855
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Topiramate is a new novel drug for the treatment of intractable seizures that is to be used in an adjunctive fashion. A review of the seven double-blind controlled studies was undertaken with special attention paid to safety and tolerability data. The studies were similar in design but used varying doses of the drug. To date there has been no evidence of serious systemic side effects such as rash, hepatotoxicity, cardiotoxicity: serious gastrointestinal toxicity or aplastic anemia. Renal stones were reported in 1.5% of patients with over 80% choosing to remain on the drug because of an improved quality of life. The unique observation of "abnormal thinking" was seen that seemed to be related to high doses and introducing the drug to rapidly. Patients, rather than describing psychomotor slowing, described a phenomenon of slow thoughts, decreased cognition, intermittent difficulty calculating, dulled thinking, blunted mental reactions. Lastly, weight loss appears in approximately 10-20% of patients and is probably related to dulling of appetite. Although increasing doses gave increasing degrees of seizure freedom, it appeared that doses beyond 600 mg/day are often not well tolerated.
引用
收藏
页码:S13 / S15
页数:3
相关论文
共 9 条
[1]   Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures [J].
BenMenachem, E ;
Henriksen, O ;
Dam, M ;
Mikkelsen, M ;
Schmidt, D ;
Reid, S ;
Reife, R ;
Kramer, L ;
Pledger, G ;
Karim, R .
EPILEPSIA, 1996, 37 (06) :539-543
[2]   Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages [J].
Faught, E ;
Wilder, BJ ;
Ramsay, RE ;
Reife, RA ;
Kramer, LD ;
Pledger, GW ;
Karim, RM ;
Barr, A ;
Fischer, J ;
Bergen, D ;
Boor, D ;
Browne, T ;
Davenport, J ;
Dichter, M ;
Drake, M ;
Kuzniecky, R ;
Mamdani, M ;
McCutchen, C ;
Naritoku, D ;
Potolicchio, S ;
Ramani, V ;
Ramsay, R ;
Shinnar, S ;
So, E ;
Wilder, B .
NEUROLOGY, 1996, 46 (06) :1684-1690
[3]   Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages [J].
Privitera, M ;
Fincham, R ;
Penry, J ;
Reife, R ;
Kramer, L ;
Pledger, G ;
Karim, R ;
Bourgeois, B ;
Carter, G ;
Ferrendelli, J ;
Fincham, R ;
Fromm, G ;
Gallagher, B ;
Harner, R ;
Holmes, M ;
Leroy, R ;
Penry, J ;
Privitera, M ;
Rosenfeld, W ;
Rowan, A ;
Sackellares, JC ;
Smith, D ;
Willmore, L ;
Wyler, A .
NEUROLOGY, 1996, 46 (06) :1678-1683
[4]  
REIFE R, 1996, EPILEPSIA S4, V37, pS74
[5]  
ROSENFELD W, 1996, EPILEPSIA S5, V37, pS153
[6]   Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy [J].
Sharief, M ;
Viteri, C ;
BenMenachem, E ;
Weber, M ;
Reife, R ;
Pledger, G ;
Karim, R .
EPILEPSY RESEARCH, 1996, 25 (03) :217-224
[7]   The epidemiology and treatment of chronic and refractory epilepsy [J].
Shorvon, SD .
EPILEPSIA, 1996, 37 :S1-S3
[8]   Safety of topiramate: Adverse events and relationships to dosing [J].
Shorvon, SD .
EPILEPSIA, 1996, 37 :S18-S22
[9]   Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy [J].
Tassinari, CA ;
Michelucci, R ;
Chauvel, P ;
Chodkiewicz, J ;
Shorvon, S ;
Henriksen, O ;
Dam, M ;
Reife, R ;
Pledger, G ;
Karim, R .
EPILEPSIA, 1996, 37 (08) :763-768